Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Treatment on Decision-making in Major Depression

NCT01916824
Conditions
Major Depressive Disorder, Healthy Controls
Interventions
Any FDA Approved Antidepressant
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Dysthymic Disorder, Dysthymia, Chronic Depressive Disorder
Interventions
Desvenlafaxine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Conditions
Major Depressive Disorder
Interventions
DVS SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
33
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 26 more
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
Conditions
Major Depressive Disorder, Recurrent, Unspecified
Interventions
LY03005, Placebo
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Marlton, New Jersey
Conditions
Depressive Disorder, Major
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
638 participants
Timeline
2006 – 2007
U.S. locations
22
States / cities
Beverly Hills, California • Burbank, California • Encino, California + 19 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam

NCT00952653
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained Release, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY03005 vs Pristiq

NCT03733574
Conditions
Major Depressive Disorder
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Arcadia, California • Beverly Hills, California • Escondido, California + 43 more
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Imperial, California + 30 more
Conditions
Menopause, Vasomotor System
Interventions
Desvenlafaxine succinate sustained-release (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
Female only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
34
States / cities
Montgomery, Alabama • Peoria, Arizona • Upland, California + 31 more
Conditions
Depressive Disorder, Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
7 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more
Conditions
Major Depression, Cancer, Diabetes, Cardiovascular Diseases
Interventions
Desvenlafaxine, Omega 3 Fatty acids, Placebo (for Omega 3 fatty acid supplement)
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
88
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
Conditions
Major Depression Disorder
Interventions
Adjunct brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
65 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Arcadia, California • Miami, Florida • Orlando, Florida + 9 more
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot BA Study of New LY03005 vs Pristiq

NCT02988024
Conditions
Major Depression
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Eatontown, New Jersey
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg, placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Encino, California • Newport Beach, California + 21 more
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Watertown, Massachusetts
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Vasomotor Symptoms
Interventions
desvenlafaxine succinate (DVS) SR, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 86 more
Conditions
Major Depressive Disorder
Interventions
DVS SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • Imperial, California + 28 more
Conditions
Healthy
Interventions
desvenlafaxine SR, venlafaxine ER
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Wichita, Kansas
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Beverly Hills, California • Encino, California • Los Alamitos, California + 16 more